ZBTB7C
geneOn this page
Also known as ZNF857C
Summary
ZBTB7C (zinc finger and BTB domain containing 7C, HGNC:31700) is a protein-coding gene on chromosome 18q21.1, encoding Zinc finger and BTB domain-containing protein 7C (A1YPR0). May be a tumor suppressor gene.
Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Involved in negative regulation of cell population proliferation. Predicted to be located in nucleus.
Source: NCBI Gene 201501 — RefSeq curated summary.
At a glance
- GWAS associations: 11
- Clinical variants (ClinVar): 95 total
- MANE Select transcript:
NM_001318841
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:31700 |
| Approved symbol | ZBTB7C |
| Name | zinc finger and BTB domain containing 7C |
| Location | 18q21.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | ZNF857C |
| Ensembl gene | ENSG00000184828 |
| Ensembl biotype | protein_coding |
| OMIM | 616591 |
| Entrez | 201501 |
Gene structure
Transcript identifiers
Ensembl transcripts: 38 — 38 protein_coding
ENST00000535628, ENST00000585404, ENST00000586047, ENST00000586438, ENST00000586525, ENST00000586743, ENST00000587107, ENST00000588028, ENST00000588053, ENST00000588149, ENST00000588566, ENST00000588970, ENST00000588982, ENST00000589077, ENST00000589170, ENST00000589194, ENST00000589619, ENST00000590178, ENST00000590374, ENST00000590437, ENST00000590800, ENST00000590855, ENST00000591279, ENST00000591405, ENST00000591526, ENST00000592387, ENST00000592656, ENST00000593159, ENST00000868923, ENST00000868924, ENST00000868925, ENST00000868926, ENST00000868927, ENST00000868928, ENST00000868929, ENST00000868930, ENST00000971936, ENST00000971937
RefSeq mRNA: 9 — MANE Select: NM_001318841
NM_001039360, NM_001318841, NM_001371284, NM_001371285, NM_001371286, NM_001371287, NM_001371288, NM_001371290, NM_001371291
CCDS: CCDS32830
Canonical transcript exons
ENST00000590800 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001307737 | 48039900 | 48041123 |
| ENSE00002744375 | 48185934 | 48185995 |
| ENSE00002793715 | 48338174 | 48338398 |
| ENSE00002874498 | 48409226 | 48409383 |
| ENSE00003844340 | 48026672 | 48029911 |
Expression profiles
Bgee: expression breadth ubiquitous, 210 present calls, max score 90.15.
FANTOM5 (CAGE): breadth broad, TPM avg 2.1842 / max 131.8059, expressed in 472 samples.
FANTOM5 promoters (9 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 171857 | 0.8969 | 202 |
| 171864 | 0.8940 | 327 |
| 171856 | 0.1195 | 60 |
| 171862 | 0.0968 | 46 |
| 171858 | 0.0510 | 28 |
| 171861 | 0.0449 | 19 |
| 171859 | 0.0416 | 21 |
| 171860 | 0.0331 | 12 |
| 171863 | 0.0064 | 4 |
Top tissues by expression
280 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| mammalian vulva | UBERON:0000997 | 90.15 | gold quality |
| esophagus mucosa | UBERON:0002469 | 90.02 | gold quality |
| bronchial epithelial cell | CL:0002328 | 89.73 | gold quality |
| gingiva | UBERON:0001828 | 89.71 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 89.65 | gold quality |
| gingival epithelium | UBERON:0001949 | 89.48 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 88.85 | gold quality |
| nipple | UBERON:0002030 | 88.48 | gold quality |
| colonic mucosa | UBERON:0000317 | 88.01 | gold quality |
| pharyngeal mucosa | UBERON:0000355 | 87.52 | gold quality |
| oral cavity | UBERON:0000167 | 87.51 | gold quality |
| mucosa of sigmoid colon | UBERON:0004993 | 87.09 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 86.33 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 86.33 | silver quality |
| skin of leg | UBERON:0001511 | 85.71 | gold quality |
| sural nerve | UBERON:0015488 | 85.62 | gold quality |
| upper leg skin | UBERON:0004262 | 85.60 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 84.99 | gold quality |
| corpus epididymis | UBERON:0004359 | 84.85 | gold quality |
| skin of abdomen | UBERON:0001416 | 84.65 | gold quality |
| zone of skin | UBERON:0000014 | 84.37 | gold quality |
| calcaneal tendon | UBERON:0003701 | 84.35 | gold quality |
| vagina | UBERON:0000996 | 84.00 | gold quality |
| right lobe of thyroid gland | UBERON:0001119 | 83.96 | gold quality |
| left lobe of thyroid gland | UBERON:0001120 | 83.81 | gold quality |
| thyroid gland | UBERON:0002046 | 83.70 | gold quality |
| penis | UBERON:0000989 | 83.69 | gold quality |
| adrenal tissue | UBERON:0018303 | 83.07 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 82.90 | gold quality |
| rectum | UBERON:0001052 | 82.83 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 2.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-CURD-119 | yes | 25.90 |
| E-ANND-3 | yes | 9.50 |
Regulation
Is transcription factor: yes
Downstream targets (CollecTRI)
3 targets.
| Target | Regulation |
|---|---|
| CDKN1A | Unknown |
| FASN | |
| NOTCH1 |
JASPAR motifs
| Motif | Name | Family |
|---|---|---|
| MA0695.1 | ZBTB7C | More than 3 adjacent zinc fingers |
| MA0695.2 | ZBTB7C | More than 3 adjacent zinc fingers |
| MA0695.3 | ZBTB7C | More than 3 adjacent zinc fingers |
JASPAR matrix evidence (PMIDs): PMID:19443739
miRNA regulators (miRDB)
116 targeting ZBTB7C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-126-5P | 100.00 | 72.71 | 3180 |
| HSA-MIR-4795-3P | 100.00 | 74.62 | 4024 |
| HSA-MIR-4510 | 100.00 | 66.60 | 2050 |
| HSA-MIR-6127 | 100.00 | 66.76 | 2188 |
| HSA-MIR-6129 | 100.00 | 66.46 | 2080 |
| HSA-MIR-6130 | 100.00 | 66.69 | 2012 |
| HSA-MIR-6133 | 100.00 | 66.48 | 2064 |
| HSA-MIR-4747-5P | 100.00 | 67.90 | 2681 |
| HSA-MIR-5196-5P | 100.00 | 67.98 | 2761 |
| HSA-MIR-4476 | 100.00 | 68.18 | 2030 |
| HSA-MIR-6876-5P | 100.00 | 67.68 | 2126 |
| HSA-MIR-3646 | 100.00 | 73.56 | 5283 |
| HSA-MIR-4776-3P | 100.00 | 68.73 | 1340 |
| HSA-MIR-450A-1-3P | 100.00 | 69.33 | 1837 |
| HSA-MIR-5193 | 100.00 | 67.26 | 1744 |
| HSA-MIR-3662 | 99.99 | 73.82 | 5684 |
| HSA-MIR-3667-3P | 99.99 | 67.17 | 1636 |
| HSA-MIR-520D-5P | 99.98 | 73.34 | 4883 |
| HSA-MIR-524-5P | 99.98 | 73.43 | 4882 |
| HSA-MIR-8068 | 99.98 | 73.85 | 2376 |
| HSA-MIR-4487 | 99.96 | 64.58 | 1252 |
| HSA-MIR-6825-5P | 99.96 | 69.81 | 3431 |
| HSA-MIR-495-3P | 99.96 | 72.81 | 4197 |
| HSA-MIR-5688 | 99.96 | 73.23 | 4504 |
| HSA-MIR-6755-5P | 99.95 | 65.59 | 464 |
| HSA-MIR-545-3P | 99.95 | 70.74 | 2783 |
| HSA-MIR-4492 | 99.87 | 68.25 | 3611 |
| HSA-MIR-4728-5P | 99.85 | 69.39 | 4718 |
| HSA-MIR-5010-3P | 99.83 | 70.60 | 2357 |
| HSA-MIR-6785-5P | 99.82 | 68.68 | 4428 |
Literature-anchored findings (GeneRIF, showing 7)
- Adm and APM-1 protect endothelium-dependent vascular relaxation in sepsis. (PMID:17932560)
- our findings define KR-POK as a transcriptional repressor with a pro-oncogenic role that relies upon binding to p53 and inhibition of its transactivation function. (PMID:22253232)
- ZBTB7C genetic variations were significant for susceptibility to ischemic injury in cerebral ischemia. (PMID:26542693)
- Repression of Kr-POK inhibited tumor growth. (PMID:28571744)
- Identification of Novel Alzheimer’s Disease Loci Using Sex-Specific Family-Based Association Analysis of Whole-Genome Sequence Data. (PMID:32193444)
- The prognostic and immunological effects of ZBTB7C across cancers: friend or foe? (PMID:33946045)
- ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression. (PMID:37121538)
Cross-species orthologs
3 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | zbtb7c | ENSDARG00000100985 |
| mus_musculus | Zbtb7c | ENSMUSG00000044646 |
| rattus_norvegicus | Zbtb7c | ENSRNOG00000047924 |
Paralogs (36): ZBTB32 (ENSG00000011590), SNAI2 (ENSG00000019549), PRDM1 (ENSG00000057657), PRDM6 (ENSG00000061455), ZNF76 (ENSG00000065029), PATZ1 (ENSG00000100105), MAZ (ENSG00000103495), ZBTB16 (ENSG00000109906), ZNF451 (ENSG00000112200), ZBTB45 (ENSG00000119574), ZNF410 (ENSG00000119725), SNAI1 (ENSG00000124216), ZNF384 (ENSG00000126746), ZBTB1 (ENSG00000126804), VEZF1 (ENSG00000136451), PRDM14 (ENSG00000147596), ZNF276 (ENSG00000158805), ZNF362 (ENSG00000160094), ZNF653 (ENSG00000161914), ZNF281 (ENSG00000162702), ZNF148 (ENSG00000163848), ZNF143 (ENSG00000166478), HIC2 (ENSG00000169635), PRDM10 (ENSG00000170325), ZNF296 (ENSG00000170684), ZNF692 (ENSG00000171163), ZNF575 (ENSG00000176472), HIC1 (ENSG00000177374), ZBTB18 (ENSG00000179456), ZBTB42 (ENSG00000179627), ZBTB20 (ENSG00000181722), SNAI3 (ENSG00000185669), ZFP91 (ENSG00000186660), MTF1 (ENSG00000188786), SCRT2 (ENSG00000215397), SCRT1 (ENSG00000261678)
Protein
Protein identifiers
Zinc finger and BTB domain-containing protein 7C — A1YPR0 (reviewed: A1YPR0)
Alternative names: Affected by papillomavirus DNA integration in ME180 cells protein 1, Zinc finger and BTB domain-containing protein 36, Zinc finger protein 857C
All UniProt accessions (6): A0A1B0GXF8, A1YPR0, B2RG49, B2RG53, B2RG63, B2RG76
UniProt curated annotations — full annotation on UniProt →
Function. May be a tumor suppressor gene.
Tissue specificity. Detected in normal cervical keratinocytes, and in some cervical carcinoma cell lines.
RefSeq proteins (9): NP_001034449, NP_001305770, NP_001358213, NP_001358214, NP_001358215, NP_001358216, NP_001358217, NP_001358219, NP_001358220 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000210 | BTB/POZ_dom | Domain |
| IPR011333 | SKP1/BTB/POZ_sf | Homologous_superfamily |
| IPR013087 | Znf_C2H2_type | Domain |
| IPR016024 | ARM-type_fold | Homologous_superfamily |
| IPR036236 | Znf_C2H2_sf | Homologous_superfamily |
| IPR050457 | ZnFinger_BTB_dom_contain | Family |
Pfam: PF00096, PF00651
UniProt features (9 total): zinc finger region 4, compositionally biased region 2, chain 1, domain 1, region of interest 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-A1YPR0-F1 | 56.80 | 0.09 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 94 (showing top):
GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, GOBP_FAT_CELL_DIFFERENTIATION, CUI_TCF21_TARGETS_2_DN, GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, GSE13762_CTRL_VS_125_VITAMIND_DAY5_DC_UP, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, DODD_NASOPHARYNGEAL_CARCINOMA_DN, chr18q21, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, PKCA_DN.V1_UP, ESC_J1_UP_EARLY.V1_UP, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY
GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), negative regulation of cell population proliferation (GO:0008285), positive regulation of fat cell differentiation (GO:0045600), positive regulation of transcription by RNA polymerase II (GO:0045944)
GO Molecular Function (5): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)
GO Cellular Component (1): nucleus (GO:0005634)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| transcription by RNA polymerase II | 2 |
| regulation of transcription by RNA polymerase II | 2 |
| RNA polymerase II transcription regulatory region sequence-specific DNA binding | 2 |
| regulation of DNA-templated transcription | 1 |
| cell population proliferation | 1 |
| regulation of cell population proliferation | 1 |
| negative regulation of cellular process | 1 |
| fat cell differentiation | 1 |
| positive regulation of cell differentiation | 1 |
| regulation of fat cell differentiation | 1 |
| positive regulation of DNA-templated transcription | 1 |
| cis-regulatory region sequence-specific DNA binding | 1 |
| chromatin | 1 |
| DNA-binding transcription factor activity | 1 |
| transition metal ion binding | 1 |
| binding | 1 |
| cation binding | 1 |
| intracellular membrane-bounded organelle | 1 |
Protein interactions and networks
STRING
672 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| ZBTB7C | MALRD1 | Q5VYJ5 | 461 |
| ZBTB7C | CTIF | O43310 | 444 |
| ZBTB7C | CLIP3 | Q96DZ5 | 443 |
| ZBTB7C | TP53 | P04637 | 436 |
| ZBTB7C | CHST8 | Q9H2A9 | 427 |
| ZBTB7C | CCDC60 | Q8IWA6 | 413 |
| ZBTB7C | PHKB | Q93100 | 412 |
| ZBTB7C | ADCY7 | P51828 | 410 |
| ZBTB7C | PCF11 | O94913 | 400 |
| ZBTB7C | CIDEC | Q96AQ7 | 391 |
| ZBTB7C | APLP1 | P51693 | 387 |
| ZBTB7C | THSD4 | Q6ZMP0 | 383 |
| ZBTB7C | SLCO6A1 | Q86UG4 | 376 |
| ZBTB7C | CSF2 | P04141 | 375 |
| ZBTB7C | CXCL8 | P10145 | 375 |
| ZBTB7C | RABEP2 | Q9H5N1 | 375 |
IntAct
5 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| RETREG1 | ZBTB7C | psi-mi:“MI:0915”(physical association) | 0.370 |
| HSCB | RBP5 | psi-mi:“MI:0914”(association) | 0.350 |
| ZBTB7C | ZBTB5 | psi-mi:“MI:0914”(association) | 0.350 |
| CDC5L | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (25): ZBTB7C (Affinity Capture-MS), JUN (Affinity Capture-Western), ZBTB7C (Affinity Capture-Western), JUN (Reconstituted Complex), ZBTB17 (Affinity Capture-Western), ZBTB7C (Reconstituted Complex), ZBTB17 (Reconstituted Complex), ZBTB7C (FRET), ZBTB7C (Affinity Capture-Western), PIAS1 (Affinity Capture-Western), ZBTB7C (Affinity Capture-Western), PIAS1 (Co-purification), ZBTB7C (Affinity Capture-MS), GATAD2B (Affinity Capture-MS), KLHL29 (Affinity Capture-MS)
ESM2 similar proteins: A0PJY2, A1YPR0, A2A935, B0K011, B0X9H6, B7ZRU9, O13089, O15090, O15156, O75626, O88939, O93567, O95365, P14404, P25932, P41183, P56260, Q03112, Q08DS3, Q0IHB8, Q1L8W0, Q2VWH6, Q32NK7, Q3T135, Q5XJQ7, Q60636, Q64321, Q6AY34, Q6DBW0, Q6F2E4, Q802Y8, Q8I7Z8, Q8K083, Q8N9L1, Q8NAP8, Q8TBJ5, Q8VCZ7, Q8VDL9, Q98T94, Q99PV8
Diamond homologs: A0A1B8YAB1, A1YPR0, B0WWP2, B1H285, B3M9V8, B3NDN0, B4GRJ2, B4HIK1, B4J045, B4L0G9, B4LIG6, B4MXW3, B4PD06, B4QLQ2, C9JR72, D3Z8N4, E0CZ16, G3X9X1, O15062, O88939, O93567, O95365, P28575, P41182, P41183, Q08CL3, Q08DK3, Q13105, Q16RL8, Q2M0J9, Q3UQV5, Q52KB5, Q5EXX3, Q5R7B8, Q5RDY3, Q5TC79, Q5ZI33, Q5ZKD9, Q5ZM39, Q60821
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
95 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 86 |
| Likely benign | 2 |
| Benign | 3 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1139 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 18:48029908:CTGC:C | acceptor_gain | 1.0000 |
| 18:48029909:TGC:T | acceptor_gain | 1.0000 |
| 18:48029910:GC:G | acceptor_gain | 1.0000 |
| 18:48029911:CC:C | acceptor_gain | 1.0000 |
| 18:48029912:C:CC | acceptor_gain | 1.0000 |
| 18:48029917:A:AC | acceptor_gain | 0.9900 |
| 18:48041119:GAGCC:G | acceptor_gain | 0.9900 |
| 18:48041121:GCC:G | acceptor_gain | 0.9900 |
| 18:48041122:CC:C | acceptor_gain | 0.9900 |
| 18:48041122:CCC:C | acceptor_gain | 0.9900 |
| 18:48041123:CC:C | acceptor_gain | 0.9900 |
| 18:48041123:CCTGC:C | acceptor_loss | 0.9900 |
| 18:48041124:C:CC | acceptor_gain | 0.9900 |
| 18:48041124:CTG:C | acceptor_loss | 0.9900 |
| 18:48041125:T:A | acceptor_loss | 0.9900 |
| 18:48096670:A:AC | donor_gain | 0.9900 |
| 18:48096671:C:CC | donor_gain | 0.9900 |
| 18:48135812:T:TA | donor_gain | 0.9900 |
| 18:48029915:C:CT | acceptor_gain | 0.9800 |
| 18:48029917:A:C | acceptor_gain | 0.9800 |
| 18:48041120:AGCC:A | acceptor_gain | 0.9800 |
| 18:48041135:C:CT | acceptor_gain | 0.9800 |
| 18:48113646:T:C | acceptor_gain | 0.9800 |
| 18:48137002:CCCA:C | donor_loss | 0.9800 |
| 18:48137003:CCA:C | donor_loss | 0.9800 |
| 18:48137004:CAC:C | donor_loss | 0.9800 |
| 18:48137006:C:CT | donor_loss | 0.9800 |
| 18:48029916:A:T | acceptor_gain | 0.9700 |
| 18:48041127:C:CT | acceptor_gain | 0.9700 |
| 18:48072587:T:C | acceptor_gain | 0.9700 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000011 (18:48328680 C>T), RS1000011950 (18:48241047 C>A), RS1000012436 (18:48370657 GA>G,GAA), RS1000027935 (18:48117598 G>C,T), RS1000040228 (18:48041967 C>A), RS1000044048 (18:48191519 G>A), RS1000057599 (18:48083023 G>C), RS1000071026 (18:48123251 A>T), RS1000086384 (18:48109589 A>G,T), RS1000092841 (18:48237425 G>A), RS1000098980 (18:48295100 C>G,T), RS1000112532 (18:48072280 C>A), RS1000113216 (18:48100083 G>A), RS1000121744 (18:48205907 C>T), RS1000128659 (18:48164829 A>C)
Disease associations
OMIM: gene MIM:616591 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
11 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004025_6 | Systemic juvenile idiopathic arthritis | 6.000000e-07 |
| GCST004749_49 | Lung cancer in ever smokers | 8.000000e-06 |
| GCST006979_272 | Heel bone mineral density | 3.000000e-09 |
| GCST006979_273 | Heel bone mineral density | 1.000000e-13 |
| GCST007843_27 | Rheumatoid arthritis | 7.000000e-09 |
| GCST008062_73 | Blood urea nitrogen levels | 2.000000e-14 |
| GCST008152_187 | Weight | 9.000000e-06 |
| GCST008758_75 | Pre-treatment viral load in HIV-1 infection | 5.000000e-16 |
| GCST008839_255 | Height | 2.000000e-08 |
| GCST010989_281 | Body size at age 10 | 2.000000e-21 |
| GCST012145_10 | Ferritin levels | 6.000000e-06 |
EFO canonical traits (5, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0009270 | heel bone mineral density |
| EFO:0004338 | body weight |
| EFO:0010125 | viral load |
| EFO:0009819 | comparative body size at age 10, self-reported |
| EFO:0004459 | ferritin measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
25 total (human), top 25 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | decreases expression, increases expression | 2 |
| Benzo(a)pyrene | affects methylation, decreases methylation | 2 |
| Valproic Acid | increases methylation, affects expression | 2 |
| Aflatoxin B1 | increases methylation, decreases expression, decreases methylation | 2 |
| perfluorotetradecanoic acid | decreases expression | 1 |
| methyleugenol | decreases expression | 1 |
| bisphenol A | affects cotreatment, affects methylation, decreases methylation | 1 |
| sodium arsenate | increases abundance, decreases expression | 1 |
| beta-lapachone | decreases expression | 1 |
| perfluorooctanoic acid | affects expression | 1 |
| aflatoxin B2 | increases methylation | 1 |
| perfluorobutyric acid | decreases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| Sunitinib | decreases expression | 1 |
| Fulvestrant | affects cotreatment, affects methylation | 1 |
| Arsenic | decreases expression, increases abundance | 1 |
| Dichlorodiphenyl Dichloroethylene | decreases expression | 1 |
| Doxorubicin | decreases expression | 1 |
| Estradiol | affects cotreatment, decreases expression | 1 |
| Ethinyl Estradiol | decreases expression | 1 |
| Lead | affects expression | 1 |
| Smoke | decreases expression | 1 |
| Triclosan | increases expression | 1 |
| Okadaic Acid | decreases expression | 1 |
| Lactic Acid | decreases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): systemic-onset juvenile idiopathic arthritis